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Evaluation of applying IHC-4 as a prognostic model in the translational study of 
Intergroup Exemestane Study (IES) – PathIES 
 
Abstract:  
Background 
Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of 
switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This 
PathIES aimed to assess the role of immunohistochemical (IHC)-4 score in determining the 
relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and 
exemestane.  
Patients and methods 
Primary tumour samples were available for 1274 patients (27% of IES population). Only 
patients for whom the 
IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 
and Ki67) were included in this analysis (N=430 patients). The clinical score (C) was based 
on age, grade, tumour size and nodal status. The association of clinicopathological 
parameters, IHC4(+C) scores and treatment effect with time to distant recurrence free 
survival (TTDR) were assessed in univariable and multivariable Cox regression analyses. A 
modified clinical score (PathIEscore) (N = 350) was also estimated. 
Results 
Our results confirm the prognostic importance of the original IHC4, alone and in conjunction 
with clinical scores, but no significant difference with treatment effects was observed. The 
combined IHC4+Clinical PathIES score was prognostic for TTDR (P<0.001) with a hazard 
ratio (HR) of 5.54 (95% CI 1.29 - 23.70) for a change from 1st quartile (Q1) to Q1-Q3 and 
HR of 15.54 (95% CI 3.70 - 65.24) for a change from Q1 to Q4. 
Conclusion 
In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients 
who remain disease-free after 2-3 years. This is a first trial to suggest extending use of 
IHC4+C score for prognostic indication for patients who have switched endocrine therapies 
at 2-3 years and who remain disease-free after 2-3 
years. 
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Introduction 
The use of aromatase inhibitors (AIs) within the adjuvant setting, either upfront or 
sequentially before or after tamoxifen, has now been established given the results of several 
international studes1-7. Recently Goss et al. reported results of MA.17R that there was a 
reduction in contralateral breast cancers and increased disease-free survival, even though no 
overall survival benefit, supporting the extended use of an AI as adjuvant endocrine therapy 
for 10 years8. However, there is still considerable uncertainty as to whether such treatment is 
necessary for all patients and whether some patients can be treated solely with either 
tamoxifen or AI alone or switched to AI following tamoxifen treatment such as was done in 
the IES trial3. The IES (Intergroup Exemestane Study) trial continues to report, even in its 
final analysis, at a median follow-up time of 12 years, a modest improvement in overall 
survival for those who ‘switched’ treatments (in preparation). 
While women with hormone receptor positive breast cancer can acquire resistance to 
endocrine treatment, it currently remains uncertain how this resistance occurs, and whether 
different mechanisms of resistance between the two treatment types exist. Several gene 
expression assays have been developed with the aim of distinguishing those patients who will 
relapse early on adjuvant endocrine therapy, including the Prosigna®, Oncotype DX®, 
EndoPredict® and Breast cancer Index™ but, as yet, none have been evaluated for their 
capacity to distinguish benefit from different forms of endocrine therapy. 
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We had established a translational group (PathIES) as part of the IES trial to evaluate the 
potential role of various candidate biomarkers to distinguish the effectiveness of tamoxifen 
and AI. This group has already reported the results of ERβ variants an its possible role in 
helping to predict appropriate endocrine therapy for patients in IES9. The 
immunohistochemical (IHC) 4+Clinical (C) score is a prognostic tool based on quantitative 
assessment of immunohistochemical biomarkers (ER, Progesterone receptor (PgR), HER2 
and Ki67) and the clinicopathologic variables (tumour grade, size, nodal status, tumour grade, 
treatment with AI or tamoxifen)10-12. The IHC4+C was developed to predict the residual risk 
of distant recurrence at 9 years in postmenopausal women with ER positive tumours treated 
with 5 years of adjuvant endocrine therapy only (i.e. no chemotherapy)13,14. However, to date, 
there is no report to evaluate the prognostic value of IHC4+C to patients who have 
receivedadjuvant tamoxifen for 2-3 years, followed by subsequent exemestane treatment to 
complete a total of 5 years endocrine therapy. We consider it important to examine the role of 
the IHC4 score in predicting prognosis in patients who are switched from tamoxifen to an AI 
since this would provide a different cohort from other studies given that we include only 
those who remain disease-free at 2-3 years. This cohort therefore excludes patients who 
relapse early but more closely resembles the cohort in whom continuation of therapy beyond 
5 years will increasingly be considered. We also report here on the role of IHC4 score in 
determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen 
and exemestane. 
 
Patients and Methods 
Study design 
IES was a multicentre, international, randomised, double-blind phase III study comparing 
exemestane 25 mg/day to tamoxifen 20 mg/day (30 mg in Denmark) for 2-3 years in 
postmenopausal women with ER+/unknown primary breast cancer who remained disease-
free after receiving adjuvant tamoxifen therapy for 2 to 3 years. The study recruited 4724 
postmenopausal women from 37 countries (366 centres) between 1998 and 2003 and has 
shown a survival benefit for those with ER+/unknown cancers from switching to exemestane 
after 2-3 years tamoxifen15,16. PathIES is a retrospective translational study that aims to 
identify markers predictive of response or resistance to tamoxifen or an AI. Pathological 
samples from the primary surgery (at least 2 years before randomisation into the main IES 
trial i.e. between 1996 and 2001) were collected retrospectively from 1274 women enrolled 
in the IES (27% of IES patients). This article presents results from the analysis of IHC4 (ER, 
PgR, HER2 and Ki67) and IHC+C (IHC4+clinical score based on nodal status, pathological 
tumour size, grade and age) on PathIES participants. Only PathIES participants for whom 
IHC4 could be calculated were included in this analysis. All clinical data used in the analyses 
were based on the snapshot taken for the most recent IES publication (median follow up time 
was 91 months)16 and the REMARK17 criteria were employed for data reporting. 
 
Patients 
Patients were eligible for enrolment in the IES study if they had histologically confirmed, 
completely resected unilateral invasive breast carcinoma positive for ERα or that was of 
unknown receptor status. Patients were postmenopausal and had received adjuvant tamoxifen 
therapy for at least two years but no more than three years and one month. The study design, 
detailed eligibility criteria and treatment schedules have been previously described3. Formalin 
fixed paraffin embedded (FFPE) tumour samples were retrospectively collected in 
accordance with institutional guidelines, ethics requirements and national laws. Laws and 
regulations at the time of tissue collection on consent requirements, collection of archived 
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FFPE samples from patients that were deceased and international sample transfers limited the 
number of countries that could participate in PathIES. 
 
Immunohistochemistry 
FFPE tissue blocks were received at the central laboratory, tissue microarrays (TMAs) were 
constructed as described9, except were lesions were of insufficient size. Pathology 
laboratories that were unable to submit FFPE tumour blocks were requested to provide 4-5 
micron whole sections. Full information on immunohistochemistry was previously 
described9. 
 
Statistical Analyses 
The primary endpoint for this study was time to distant recurrence (TTDR) defined as time 
from random assignment to treatments to distant recurrence, death from breast cancer or 
unknown cause without prior recurrence. The clinicopoathological characteristics of patients 
selected for this analysis to those not selected (due to unavailable tissue for the analysis, or 
unavailable markers for IHC4 assessment) were tabulated. No allowance has been made for 
multiple testing. 
 
Calculation of IHC4 score & evaluation of its prognostic value among PathIES participants 
Analysis was limited to ER+ve PathIES patients as assessed centrally by either ≥1% positive 
stained cells or H score ≥1 or Allred ≥3. The Cuzick10et al.algorithm was adopted as follows, 
to derive the IHC4 score, which in combination with a clinical score (nodes, grade, age, 
tumour size) was tested for its prognostic value on our data. 
 
𝐼𝐻𝐶4 = 94.7 𝑥 [−0.1 𝐸𝑅10 − 0.079 𝑃𝑔𝑅10 + 0.586 𝐻𝐸𝑅2 + 0.240 𝑥 ln(1 + 4 𝑥 𝑘𝑖67)] 
 
𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑠𝑐𝑜𝑟𝑒 = 100 𝑥 [0.417 𝑁1−3 + 1.566 𝑁>3 + 0.93 𝑥 (0.497 𝑇1−2 + 0.882 𝑇2−3 
+ 1.838 𝑇>3 + 0.559 𝐺𝑟2 + 0.970 𝐺𝑟3 + 0.130 𝐴𝑔𝑒>65] 
 
In brief, the ER10 was equivalent to ER H-score divided by 30 and PgR10 equivalent to PR 
percentage of positive tumour nuclei cells divided by 10. The range of ER10 and PgR would 
be 0 to 10. HER2 was considered positive if IHC staining was 3+ and negative for IHC 0, 1+, 
2+. Ki67 score was transformed as ln(1+(4*ki67). The IHC4 risk groups were categorized as 
follows: quartile (Q) 1: < 25% , Q2-Q3: ≥ 25% and < 75%, Q4: ≥ 75 %). For the clinical 
score, Nj, Tj, Grj and Agej denote categories of nodal status (N0, 1-3N+ve, >3N+), tumour 
size (<1 cm (T0), 1-2 cm (T1-2), 2-3 cm (T2-3), and >3cm (T>3)), grade (I, II, III) and age (<65, 
≥65). The anastrozole vs. tamoxifen effect term was deemed inappropriate for the exemestane 
effect on the PathIES data to validate the prognostic model of IHC4+C therefore it was 
omitted. The IHC4+C risk groups were also categorised based on the quartiles (Q) (Q1: <25 
% vs Q2-Q3: ≥25% and <75 % vs Q4: ≥75 % -). 
Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models, as appropriate, 
were used to compare how time to distant recurrence varied according to the IHC4 and 
IHC4+C risk groups. The significance of treatment effect with risk groups were determined 
by an interaction test in the multivariable Cox model.  
A calibration plot, comparing the predicted and observed probability of distant relapse by 10 
years assessed the performance of the IHC4+C prognostic score. Patients were divided into 
10 groups according to their 10th’s percentiles of IHC4+C score; mean predicted values 
within each group were compared to the observed Kaplan-Meier estimates obtained for each 
group at 10 years. 
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Adjusting the prognostic clinical score model using PathIES parameters  
To retain the comparability with the original IHC4+C model as reported by Cuzick et al., we 
used the same criteria to categorize the following variables: age, nodal status, tumour size and 
grade. The association of clinicopathological parameters, IHC4 score (included as continuous 
variable) and the PathIES treatment effect (tamexem vs tam alone) with survival data were 
assessed in a univariable Cox regression analysis. For the multivariable Cox regression 
analysis, we applied a stepwise backward strategy to select the most prognostic factors, while 
forcing the selection to keep treatment in the model, as assessed by a significance level of 
10% if not lower. 
 
Results 
Characteristics of PathIES participants 
Of the 4724 postmenopausal women with ER+ve/unknown primary breast cancer included in 
the IES trial, 1483 from 89 centres were recruited into PathIES study. Of those, material was 
available for 1274 women, 27% of the IES population or 85% of the population recruited 
from centres participating in PathIES (Supplementary Table 1). 
 
IHC4 Scores 
Of the 1274 cases, 800 were confirmed as ER+ by centralised review (Figure 1). Interpretable 
immunohistochemical data for IHC4 markers were only available for 430 women of whom 
350 had complete set of data for all clinical factors used in the analysis. In these 350 patients, 
there were 105 recurrences of which 67 were distant recurrences. Table 1 outlines the 
characteristics of those patients with available data on all IHC4 markers (n=430) and those 
without (n=4294) within IES population. 
 
Part A: Performance of IHC4 and IHC4+C on PathIES 
Of 430 ER+ve patients, 393 (91%) were PgR +ve, 186 (43%) expressed high proliferation 
(Ki67>=13%) and 20 (4.7%) were HER2+ve. The median IHC4 score on PathIES data was -
19.2 [IQR -51.5, 10.2] whilst in the ATAC population this was -  4.2 [IQR -29.9, 29.9]. The 
HR for a change from the 1st quartile (Q1) to the Q2-Q3 was 1.45 (95% CI 0.73 to 2.88) and 
from Q1 to Q4 it was 2.32 (95% CI 1.13 to 4.73) (P=0.04, Figure 2a and Table 2). Within 
treatment group, and possibly due to the low number of events and lack of power, IHC4 was 
no longer prognostic. No interaction was detected between IHC4 and treatment group 
(interaction P=0.96). The addition of the clinical score to the IHC4 score resulted in more 
profound effects in separating patients associated with differential risks (Figure 2b and Table 
2).  
Predicted probabilities of distant relapse at 10-yr using IHC4+C (minus the treatment effect) 
were calculated. Fifty per cent of patients had predicted risk of relapse ≤ 10%, with 25% of 
patients with predicted risk of relapse over 20%. When comparing the observed and predicted 
probabilities of distant relapse at 10-yr using IHC4+C (minus the treatment effect), the 
agreement between observed and predicted probabilities was good as shown by the 
calibration plot (Figure 2c), though there is higher variability in patients with predicted risk 
of relapse >10%. 
 
Part B: Adjusting the clinical model using PathIES parameters 
PathIES patients had received adjuvant tamoxifen therapy for at least 2-3 years before trial 
entry therefore it was of particular interest to ascertain which clinical variables remain 
prognostic after this time interval. Nodal status, tumour size and IHC4 demonstrated a highly 
significant prognostic value when associated univariately with time to distant recurrence 
6 
 
(Table 3). Such association remained in the multivariable model after backwards selection. 
The modified PathIES prognostic score was calculated as: 
 
𝐼𝐻𝐶4 + 𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑃𝑎𝑡ℎ𝐼𝐸𝑆 𝑠𝑐𝑜𝑟𝑒 
= 100 𝑥 (−0.13 𝑥 𝑒𝑥𝑒 + 0.46 𝑁1−3 + 1.45 𝑁>3 + 1.37 𝑇1−2 + 1.65 𝑇2−3 + 2.21 𝑇>3 + 0.0048 
𝐼𝐻𝐶4) 
 
where Nj and Tj, denote categories of nodal status (N0, 1-3N+ve, >3N+ve) and tumour size 
(T0, T1-2, T2-3, T>3) as described above for the IHC4+C score. For ease of interpretation, the 
score has been multiplied by 100. After computing this score for all patients, and categorised 
into three groups with cut-offs 25 % and 75 %, Figure 3a shows Kaplan-Meier curves for 
these groups according to the IHC4+Clinical PathIES score. 
The combined IHC4+Clinical PathIES score was highly prognostic for outcome (P<0.001): 
HR 5.54, 95% CI (1.29 – 23.70) for a change from Q1 to Q2-Q3 and HR 15.54, 95% CI (3.70 
– 65.24) for a change from Q1 to Q4  (added to Table 2 for comparison). Figure 3b shows the 
relationship of the combined IHC4+Clinical PathIES score with the risk of distant recurrence 
after 9 years according to nodal status. 
 
Discussion 
To our knowledge, this is the first time that the IHC4 and IHC4 + Clinical score has been 
tested for its ability to predict relapse in a cohort of patients who switched to an AI at 2-3 
years, thus excluding those who relapsed early and more closely resembling the cohort who 
would potentially be considered for extended adjuvant therapy beyond 5 years. We found that 
patients with a IHC 4 + Clinical score of ≥75th percentile have an approximately 50% risk of 
recurrence by 10 years after switching at 2-3 years. This may imply that this subgroup should 
continue adjuvant endocrine therapy beyond the total of 5 years. Prediction of late relapse is a 
matter of considerable concern for patients who have switched therapies at 2-3 years and who 
remain disease-free after 2-3 years, since the current and planned randomised studies are 
insufficiently mature to assist their decision-making at the current time. 
The IHC4 score has been confirmed as being predictive of early relapse by a number of 
groups, and is known to be especially valuable when combined with clinical prognostic 
scores10. Recently it has been compared with other scoring systems for its ability to predict 
both early and late recurrences18,19; although the PAM50 risk of recurrence (ROR) score was 
superiors in this study, the IHC4 has been found to be an important scoring system. 
Our results confirm the prognostic importance of IHC4, alone and in conjunction with 
clinical scores. Although results from the calibration plot indicated that the prediction based 
on the published IHC4+C derived from TransATAC study was higher than the actual 
observed probability in some groups of predicted risk >10%; one possible reason for this is 
that PathIES patients were treated with tamoxifen for 2-3 years, and remained recurrence-free 
before being randomised. Our results, nevertheless, demonstrated the prognostic value of 
IHC4 to segregate patients associated with differential risks of recurrence. The predictive 
value of the calculator might be improved by adjusting the weight estimates for each of the 
factors, given this is a different population and potential prognostic time dependency of some 
of the clinical pathological variables. Additional study using an independent cohort of 
patients is needed to investigate the robustness of the estimates. 
Several other scoring systems have been advocated for their ability to predict late recurrence 
in patients with ER positive breast cancer; Sestak et al19 compared IHC4, recurrence score 
(RS) as well as the PAM50 ROR score in patients enrolled in the ATAC study: here, node 
status, tumor size and the ROR score, a gene expression profile test, were the factors best 
able to predict long term relapse. More recently, the TransATAC group compared the Breast 
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Cancer Index (BCI), (both linear and cubic) the OncotypeDX, as well as the IHC4 score; here 
the BCI (linear) had the best predictive value20. The components of this score that were most 
important were HOXB13/IL17BR. The reason for these two factors being so important 
appears to be that HOXB3 can over-ride the tumour suppressor p21 whilst IL17 is now 
known to be a the prime neutrophil-dependent growth promoter in breast cancer21. The 
importance of this ratio was also underscored by the reports on retrospective analysis of the 
ratio in the MA17 study and predicted those who may benefit from extended letrozole 
therapy22. Recently, TransATAC group reported that EndoPredict (EPclin), an alternative test 
combining an eight-gene signature (EP score) with tumor size and nodal status, provided 
more prognostic information than the OncotypeDX score for estimating late recurrence23, 
which may partly due to the reason that the test includes the significant clinicopathological 
variables. 
Previously, an assessment of the predictive effects, in terms of therapy, of Ki67 had been 
reported by Viale et al24. This report suggested that high Ki67 levels predicted benefit from 
aromatase inhibition. However, this result was not amalgamated with the other three 
components of the IHC4 score, namely ER, PR and HER-2. In the current study, there were 
too few patients to enable an assessment of the IHC4 score for its capacity to predict which 
patients benefit from tamoxifen or exemestane after 2-3 years. 
Recently we carried out immunohistochemical staining for ER beta 1 and 2 in a subset of 
patients. Here, we found that, for those patients whose tumours expressed ER beta 1, the 
beneficial effect of simply continuing tamoxifen was similar to the patients who switched 
treatment to exemestane. Although requiring confirmation, this study suggests that it may be 
possible to ‘tailor’ treatment according to the primary tumour characteristics. This, combined 
with the IHC4+clinical score, should enable us to optimise the type and duration of endocrine 
therapy. 
There are a few caveats before translating these results into clinical practice; firstly, these 
patients did not receive trastuzumab; the study was initiated before the studies of adjuvant 
trastuzumab were mature and adjuvant trastuzumab became standard practice for patients 
whose tumors expressed HER-2; however, only 5% of patients had HER2 over-expressed 
tumours in this study. Secondly, Ki67 measurement, despite being the subject of a recent 
consortium statement remains a challenging analyte in tissue sections, due principally to 
heterogeneity of expression25,26. Thus, all the Ki67 value were analysed and assessed in one 
central laboratory. Finally, although tissue markers reflect the biology of breast cancers in 
large series such as this, they do not enable clinicians to accurately predict the type and 
duration of treatment for individual patients; this is reflected by our finding here that 
approximately 50% of those with the highest quartile of the IHC4+ clinical score have not yet 
relapsed. 
Other methods of predicting effectiveness and duration of treatment include the assessment of 
cell-free DNA; using sensitive detection methods it is possible to detect circulating DNA 
from apoptosing residual breast cancer cells; it has now been shown that copy number 
variation27 and detection of mutations28 potentially can predict which patients are resistant to 
therapy. 
In summary, the IHC4 score is useful in predicting long-term relapse in patients who remain 
disease-free after 2-3 years. Future, prospective studies are needed to define the role of IHC4 
in selecting patients for long-term therapy. 
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Figure 1. Consort diagram 
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Figure 2a: Time to distant recurrence according to quartiles (Q) of IHC4 score (Q1: <25 % 
vs Q2-Q3: ≥25 % and <75 % vs Q4: ≥75 %) (N = 430)  
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Figure 2b: Time to distant recurrence according to quartiles (Q) of the combined 
IHC4+Clinical score (Q1: <25 % vs Q2-Q3: ≥25 % and <75 % vs Q4: ≥75 %) (N = 350). Of 
note, the clinical score did not include the treatment component 
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Figure 2c: Calibration plot of predicted vs. observed probability of distant recurrence by 10 
years for each 10th percentile of the IHC4 + Clinical score (N = 350). DR = distant 
recurrence. 
(NB: Perfect predictions should be on the 45 line.) 
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Figure 3a: Time to distant recurrence according to quartiles of the combined IHC4+Clinical 
PathIES score (N = 350) (Q1: <25 % vs Q2-Q3: ≥25 % and <75 % vs Q4: ≥75 %) 
(NB: The model adjusts for the PathIES treatment effect) 
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Figure 3b: Predicted 9-year distant recurrence probabilities for different nodal status according to 
IHC4 + Clinical PathIES score (N=350) 
 
 
 
Supplementary Table 1: Baseline clinical characteristics for patients who did and did 
not have IHC4 score within PathIES participating sites and in non-participating sites.  
HRT: hormone replacement therapy. * Chi2 test calculation includes only Grades 1, 2, 
3/undifferentiated.   
 
 Centres that provided tissue Centres that did 
not provide 
tissue 
Patients 
with 
IHC4 
score 
Col % Patients 
without 
tissue 
/score 
Col % Patients 
without 
tissue 
/score 
Col % 
Tumour grade             
1 97 23 175 16 517 16 
2 209 49 424 39 1354 42 
3 / Undifferentiated 78 18 200 19 645 20 
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Not assessable 2 0 25 2 76 2 
Unknown 44 10 252 23 626 19 
Chi2 trend test - within centre* p=0.15     
Chi2 trend test - with and 
without tissue/score* p=0.03 
Treatment arm             
Exemestane 222 52 536 50 1594 50 
Tamoxifen 208 48 540 50 1624 50 
Chi2 test - within centre p=0.53     
Chi2 test - with and without 
tissue/score p=0.42 
Nodal status             
Negative 193 49 483 48 1771 56 
1-3 N+ 143 36 377 37 911 29 
4-9 N+ 42 11 115 11 329 10 
≥10 N+ 17 4 40 4 115 4 
Chi2 trend test - within centre p=0.94     
Chi2 trend test - with and 
without tissue/score p=0.15 
Age group              
<60 142 33 350 33 1031 32 
60 - 69 191 44 481 45 1349 42 
70+ 97 23 245 23 838 26 
Chi2 test - within centre p=0.98     
Chi2 test - with and without 
tissue/score p=0.47 
Previous chemotherapy use             
No 354 82 849 79 1979 62 
Yes 76 18 227 21 1239 39 
Chi2 trend test - within centre p=0.14     
Chi2 trend test - with and 
without tissue/score p<0.001 
HRT use             
17 
 
Yes 145 34 289 28 690 22 
No 276 66 734 72 2477 78 
Chi2 test - within centre p=0.02     
Chi2 test - with and without 
tissue/score p<0.001 
Histological type             
Infiltrating ductal 329 77 775 72 2503 78 
Infiltrating lobular 53 12 172 16 437 14 
Other 48 11 129 12 269 8 
Chi2 test - within centre p=0.15     
Chi2 test - with and without 
tissue/score p=0.30 
Tumour size group (cm)             
≤2cm 246 58 640 61 1899 60 
>2 - ≤5cm 168 39 377 36 1171 37 
>5cm 13 3 25 2 84 3 
Chi2 trend test - within centre p=0.36     
Chi2 trend test - with and 
without tissue/score p=0.48 
 
 
